Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Interleukin-10: a cytokine used by tumors to escape immunosurveillance.

Literature DB >> 10456656

Interleukin-10: a cytokine used by tumors to escape immunosurveillance.

Abstract

The mechanisms whereby malignant cells can elude the recognition of the immune system, by what is termed 'immunological escape', have attracted major attention of tumor immunologists during the past decade. In this review, the role of the immunosuppressive cytokine interleukin-10 (IL-10) will be discussed as a strategy used by tumors to avoid recognition by cytotoxic T lymphocytes (CTL).

Entities: Disease Gene

Mesh：

Substances：

Year: 1999 PMID： 10456656 DOI： 10.1007/bf02785841

Source DB: PubMed Journal: Med Oncol ISSN： 1357-0560 Impact factor: 3.064

94 in total

Review 1. Generation, intracellular transport and loading of peptides associated with MHC class I molecules.

Authors: J O Koopmann; G J Hämmerling; F Momburg
Journal: Curr Opin Immunol Date: 1997-02 Impact factor: 7.486

2. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression.

Authors: F Salazar-Onfray; M Petersson; L Franksson; M Matsuda; T Blankenstein; K Kärre; R Kiessling
Journal: J Immunol Date: 1995-06-15 Impact factor: 5.422

3. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration.

Authors: G Richter; S Krüger-Krasagakes; G Hein; C Hüls; E Schmitt; T Diamantstein; T Blankenstein
Journal: Cancer Res Date: 1993-09-15 Impact factor: 12.701

4. An active T-cell-independent mechanism enhances MHC class I transcription and expression on a mouse T-cell lymphoma in vivo.

Authors: M G Petersson; K Kärre; M Cochet; P Kourilsky; R Kiessling
Journal: Cell Immunol Date: 1987-09 Impact factor: 4.868

5. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells.

Authors: J Péguet-Navarro; C Moulon; C Caux; C Dalbiez-Gauthier; J Banchereau; D Schmitt
Journal: Eur J Immunol Date: 1994-04 Impact factor: 5.532

6. Expression of transforming growth factor-beta 1 in prostate cancer.

Authors: M S Steiner; Z Z Zhou; D C Tonb; E R Barrack
Journal: Endocrinology Date: 1994-11 Impact factor: 4.736

7. Altered immune responses in interleukin 10 transgenic mice.

Authors: A Hagenbaugh; S Sharma; S M Dubinett; S H Wei; R Aranda; H Cheroutre; D J Fowell; S Binder; B Tsao; R M Locksley; K W Moore; M Kronenberg
Journal: J Exp Med Date: 1997-06-16 Impact factor: 14.307

8. A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.

Authors: N P Restifo; P J Spiess; S E Karp; J J Mulé; S A Rosenberg
Journal: J Exp Med Date: 1992-06-01 Impact factor: 14.307

9. Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators.

Authors: M P Schrey; K V Patel
Journal: Br J Cancer Date: 1995-12 Impact factor: 7.640

10. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.

Authors: P Korkolopoulou; L Kaklamanis; F Pezzella; A L Harris; K C Gatter
Journal: Br J Cancer Date: 1996-01 Impact factor: 7.640

27 in total

1. Immune complex-stimulated production of interleukin-12 in peripheral blood mononuclear cells is regulated by the complement system.

Authors: A Tejde; L Mathsson; K N Ekdahl; B Nilsson; J Rönnelid
Journal: Clin Exp Immunol Date: 2004-09 Impact factor: 4.330

2. Skin cancer in asians: part 1: nonmelanoma skin cancer.

Authors: Grace K Kim; James Q Del Rosso; Susun Bellew
Journal: J Clin Aesthet Dermatol Date: 2009-08

3. Haplotype-dependent differential activation of the human IL-10 gene promoter in macrophages and trophoblasts: implications for placental IL-10 deficiency and pregnancy complications.

Authors: Surendra Sharma; Joan Stabila; Linda Pietras; Arvind R Singh; Bethany McGonnigal; Jan Ernerudh; Leif Matthiesen; James F Padbury
Journal: Am J Reprod Immunol Date: 2010-09 Impact factor: 3.886

Interleukin-10: a cytokine used by tumors to escape immunosurveillance.

Review 1. Generation, intracellular transport and loading of peptides associated with MHC class I molecules.

2. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression.

3. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration.

4. An active T-cell-independent mechanism enhances MHC class I transcription and expression on a mouse T-cell lymphoma in vivo.

5. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells.

6. Expression of transforming growth factor-beta 1 in prostate cancer.

7. Altered immune responses in interleukin 10 transgenic mice.

8. A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.

9. Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators.

10. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.

1. Immune complex-stimulated production of interleukin-12 in peripheral blood mononuclear cells is regulated by the complement system.

2. Skin cancer in asians: part 1: nonmelanoma skin cancer.

3. Haplotype-dependent differential activation of the human IL-10 gene promoter in macrophages and trophoblasts: implications for placental IL-10 deficiency and pregnancy complications.

Review 4. Dendritic cell control of tolerogenic responses.

Review 5. Tregs and rethinking cancer immunotherapy.

6. Molecular pathology of primary intraocular lymphoma.

7. Immunoregulation through IL-10 gene expression and the fate of cytotoxic T lymphocyte-mediated tumor immunotherapy.

8. Effect of prolactin on carcinoembryonic antigen-specific cytotoxic T lymphocyte response induced by dendritic cells.

9. Chemotherapeutic drugs and human tumor cells cytokine network.

Review 10. ProtEx technology for the generation of novel therapeutic cancer vaccines.